Thymus, thymulin and anti-ageing: what the science really says

Thymus, thymulin and anti-ageing: what the science really says

An organ that disappears before our eyes

There is an organ in our body that, from puberty onwards, begins methodically to self-destruct. It is not a disease, nor an accident of evolution: it is a perfectly normal biological programme called thymic involution. And it may well be one of the most powerful drivers of our ageing.

The thymus is a small, soft, pinkish organ with two lobes, located just behind the breastbone, in front of the heart and the great vessels, in an anatomical region called the anterior mediastinum. In a newborn it weighs about fifteen grams and takes up considerable space in the chest — so much so that on an infant's X-ray it is sometimes mistaken for an abnormality. It reaches its maximum weight, about 30 to 40 grams, at puberty. Then, year after year, its functional tissue is replaced by fat. By 50, often only around ten percent of active thymic tissue remains. By 70, it can barely be told apart from the surrounding fat.

This programmed disappearance is far from trivial, because the thymus is not a decorative organ. It is the training school for T lymphocytes, the immune cells that bear its initial ("T" for thymus) and form the armed wing of our adaptive immunity. Without a functioning thymus, there are no new naive T cells — that is, no "blank" cells able to learn to recognise a pathogen never met before.

The importance of this organ is painfully clear in children with complete DiGeorge syndrome, a rare genetic disease (22q11.2 deletion) in which the thymus does not develop: without a thymus tissue transplant, these children die of infections in their first years of life. This condition led to the development of a therapy approved by the FDA in 2021, Rethymic, cultured thymus tissue implanted surgically.

What the thymus actually produces

To understand why researchers in the biology of ageing are so interested in it, you need to grasp what happens inside.

T cell precursors are born in the bone marrow, then migrate to the thymus. There, they undergo an extremely demanding two-stage training:

  1. Positive selection: the young lymphocyte must prove that it can recognise "self" molecules (the major histocompatibility complexes). If it cannot, it is eliminated — it would be useless.

  2. Negative selection: it must then show that it does not react too violently against the body's own tissues. Thanks to a remarkable gene called AIRE (AutoImmune REgulator), the medullary epithelial cells of the thymus display fragments of proteins from all over the body — insulin, myelin, thyroglobulin… Any lymphocyte that attacks them too eagerly is destroyed on the spot.

At the end of this process, more than 95% of the candidate cells die in the thymus. Only the graduates — competent but tolerant — leave for the bloodstream. It is this ruthless filter that protects us from both infection and autoimmunity.

The thymus also produces peptide hormones, making it both an immune and an endocrine organ. The main ones are thymopoietin, thymosin α1, thymic humoral factor… and thymulin, which is of particular interest here.

Thymulin: a nine-amino-acid hormone and a zinc atom

Thymulin has a French scientific history. It was isolated and characterised in the 1970s by the team of Jean-François Bach at the Necker hospital in Paris, under the original name FTS (Facteur Thymique Sérique, serum thymic factor). Its structure was published in 1977: it is a nonapeptide, a chain of nine amino acids (Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), secreted by thymic epithelial cells.

Its special feature is fascinating: thymulin is only biologically active when bound to a zinc atom. Without zinc, the molecule exists but remains inert. It is the zinc–thymulin complex that has hormonal activity. This dependence has a direct clinical consequence: in zinc deficiency, thymulin activity collapses — and that is precisely what is seen in older people, among whom zinc deficiency is common. Work led notably by Eugenio Mocchegiani in Italy showed that zinc supplementation could partly restore thymulin activity in older people.

Functionally, thymulin is involved in T cell differentiation, modulates cytokine production, and takes part in the constant dialogue between the immune system and the central nervous system — notably affecting the hypothalamic–pituitary axis. Research has also shown anti-inflammatory and analgesic properties in animal models, which has prompted interest in applications outside immunology.

The crucial point for our subject: blood thymulin levels fall with age. Abundant in children, they become very low or even undetectable after the age of fifty. This decline closely follows thymic involution, which has made thymulin a biomarker of residual thymic activity — and an obvious candidate for immune rejuvenation strategies.

Immunosenescence: why it concerns us all

The weakening of the thymus is not a laboratory detail. It is at the heart of a now well-documented phenomenon: immunosenescence, the ageing of the immune system.

In practice, with age:

  • The repertoire of naive T cells shrinks. We still have memory T cells, trained against agents we have already met, but our ability to respond to a new pathogen falls sharply. This is one of the explanations for the severity of Covid-19 in older people, and for the lower effectiveness of vaccines after 65.
  • Anti-tumour surveillance weakens, which contributes to the exponential rise in cancer incidence with age.
  • Control of autoimmunity deteriorates, linked to poorer negative selection and declining AIRE expression.
  • A state of chronic low-grade inflammation sets in, dubbed inflammaging, now considered a cross-cutting risk factor for cardiovascular, neurodegenerative and metabolic diseases.

Thymic involution is thus closely linked to several of the "hallmarks of aging", the fundamental markers of ageing described by biologists (chronic inflammation, altered intercellular communication). Hence a question that long seemed like science fiction: what if we could make the thymus grow back?

The TRIIM trial: the thymus that rejuvenates

In September 2019, a publication in the journal Aging Cell caused a stir. It reported the results of the TRIIM study (Thymus Regeneration, Immunorestoration and Insulin Mitigation), led by Gregory Fahy and Steve Horvath, the latter the inventor of the famous "epigenetic clocks".

The protocol: nine healthy male volunteers, aged 51 to 65, treated for a year with a combination of recombinant human growth hormone (rhGH), DHEA and metformin. The logic: growth hormone is known to stimulate thymic tissue, while DHEA and metformin were there to counter its diabetogenic effect.

The results were twofold and spectacular:

  • MRI showed partial regeneration of thymic tissue, with fat replaced by functional tissue in seven of the nine participants, along with improvements in several immune parameters (CD4/CD8 T cell ratio, NK cells, naive T cells).
  • More unexpectedly, analysis of epigenetic clocks revealed an average biological rejuvenation of 1.5 to 2.5 years depending on the clock used, an effect that seemed to persist six months after treatment ended.

According to the authors, it was the first demonstration in humans of a measurable reversal of biological age.

But this must immediately be tempered. The trial has major limitations that its own authors acknowledge: only nine participants, no control group, no placebo, an exclusively male, white, healthy population, and epigenetic clocks that remain research tools whose clinical interpretation is debated. A larger follow-up trial, TRIIM-X, including men and women and a control group, has been launched — its full results are awaited by the scientific community with great interest, but also with great caution.

Key point: recombinant growth hormone is not a harmless product. Its misuse for anti-ageing purposes carries real risks — oedema, carpal tunnel syndrome, joint pain, insulin resistance and diabetes, and an unresolved question of cancer risk (the GH/IGF-1 axis promotes cell proliferation). Using it outside a medical indication is neither authorised nor recommended.

Other avenues of research

The thymus is now a very active field of research, well beyond the TRIIM trial alone.

Blocking sex hormones. Thymic involution speeds up markedly at puberty, and sex steroids are largely responsible. In animals as in humans, chemical castration (with LHRH agonists) causes documented thymic regeneration. This approach has been tested in patients receiving a bone marrow transplant, with encouraging results for immune reconstitution — but its side effects obviously rule it out as a general anti-ageing strategy.

Cytokines and growth factors. Interleukin-7 (IL-7), KGF/palifermin and ghrelin have shown the ability to regenerate the thymus in preclinical models and in a few targeted clinical trials (immune reconstitution after chemotherapy, HIV infection).

Tissue engineering. This may be the most promising long-term avenue. Teams, notably at the University of Edinburgh around Clare Blackburn, have managed to regenerate a functional thymus in old mice by reactivating a key transcription factor, FOXN1, whose expression declines with age. Other work focuses on building artificial thymuses from decellularised scaffolds or organoids derived from induced pluripotent stem cells (iPSCs). Rethymic, mentioned above, shows that thymus tissue transplantation is technically feasible in humans.

Zinc. A much more modest but accessible avenue: since thymulin needs zinc, correcting a proven zinc deficiency in older people restores some thymulin activity and improves some immune parameters. Be careful, though: this is about correcting a deficiency, not taking high-dose supplements. Chronic excess zinc induces copper deficiency and anaemia and can, paradoxically, depress immune function. Reference intakes are around 9 to 14 mg/day for adults, and the upper safe limit set by EFSA is 25 mg/day, from all sources combined.

The anti-ageing market: where great caution is needed

This is where the subject becomes sensitive, because the promise of "regrowing your thymus" is commercially irresistible — and supply has grown far faster than the evidence.

Bovine thymus extracts. Sold as capsules or injectable ampoules, they are presented as a natural source of "thymic hormones". There are three fundamental problems. First, peptides taken by mouth are digested: nothing guarantees that they reach the bloodstream in active form. Second, using tissue of bovine origin raises a health safety question — the risk of transmitting unconventional pathogens has remained a formal concern since the BSE crisis. Finally, the level of clinical evidence remains very low: a few old, small, methodologically weak studies.

Synthetic peptides. Thymosin α1 (Zadaxin) is a real medicine, approved in several countries for chronic hepatitis B and used as an adjuvant in some settings. It is not an anti-ageing product. Thymalin and Thymogen, developed in Russia, are widely promoted in "biohacking" circles, but their international, peer-reviewed evidence base is thin. As for peptides sold online as "research use only", they escape all pharmaceutical quality control: uncertain composition, possible contaminants, fanciful dosages. Injecting these products is an unquantified risk.

Fresh cell therapy (Frischzellentherapie), which involves injecting cells from foetal animal organs, including the thymus, is offered in some clinics. It has no scientific basis and has been associated with serious anaphylactic reactions and cases of encephalitis. It is banned or strictly restricted in several countries.

The most serious theoretical risk, finally, is too rarely mentioned: stimulating immune proliferation is not neutral. Poorly controlled thymic regeneration could, in theory, break immune tolerance and promote autoimmune conditions, or stimulate unwanted cell clones. That is precisely why these approaches must remain within rigorous clinical trials.

What remains reasonable today

Does that mean giving up on looking after your thymus? No — but the levers available are more prosaic than fashionable peptides, and they, at least, are solidly documented.

Zinc status deserves attention after 65, ideally after a blood test rather than blindly. Regular physical activity has shown favourable effects on several markers of immunosenescence, including the production of naive T cells. Controlling abdominal weight matters, as obesity speeds up thymic involution. Sleep and managing chronic stress directly influence the neuro-immuno-endocrine axis of which thymulin is one of the messengers, cortisol being a powerful inducer of thymic atrophy. Finally, vaccination remains, in older people, the most effective way to make up for a depleted immune repertoire.

The thymus is a wonderful object of science, and it is plausible that its regeneration will one day become a real medical intervention. But we are not there yet. Between nine volunteers without a control group and a validated therapy lies the distance between an attractive hypothesis and proof — and that is exactly the distance anti-ageing marketing tries to make us forget.

Disclaimer

This article is strictly for information and in no way constitutes medical advice. No supplementation, let alone any injection of peptides, thymus extracts or growth hormone, should be undertaken without a doctor's advice. The misuse of recombinant growth hormone is illegal in many countries and carries proven health risks.

Sources

← Back to articles